Placebo Effects on the Immune Response in Humans: The Role of Learning and Expectation

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Albring, Antje ^a   Wendt, Laura ^a   Benson, Sven ^a   Witzke, Oliver ^b   Kribben, Andreas ^b   Engler, Harald ^a   Schedlowski, Manfred ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIBODY; CYCLOSPORIN A; INTERLEUKIN 2; PLACEBO;

ADULT; ARTICLE; CELL STIMULATION; CLINICAL PROTOCOL; CONDITIONING; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; EVENING DOSAGE; EXPECTATION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LEARNED IMMUNOSUPPRESSION; LEARNING; MALE; MORNING DOSAGE; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIAL; STIMULUS RESPONSE;

ADOLESCENT; ADULT; BEHAVIOR; CD4-POSITIVE T-LYMPHOCYTES; CONDITIONING, CLASSICAL; CYTOKINES; DOUBLE-BLIND METHOD; HUMANS; IMMUNE SYSTEM; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; LEARNING; LEUKOCYTES, MONONUCLEAR; MALE; NEUROPSYCHOLOGICAL TESTS; PLACEBO EFFECT; PLACEBOS; T-LYMPHOCYTES;

EID: 84869747431     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049477     Document Type: Article

References (40)

1. Finniss DG, Kaptchuk TJ, Miller F, (2010) Biological, clinical, and ethical advances of placebo effects. Lancet 375: 686-695.
2. Price D, Finniss D, Benedetti F, (2008) A comprehensive review of the placebo effect: recent advances and current thought. Annu Rev Psychol 59: 565-590.
3. Benedetti F, Arduino C, Amanzio M, (1999) Somatotopic activation of opioid systems by target-directed expectations of analgesia. J Neurosci 19: 3639-3648.
4. Zubieta J-K, Bueller JA, Jackson LR, Scott DJ, Xu Y, et al. (2005) Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. J Neurosci 34: 7754-7762.
5. de la Fuente-Fernández R, Ruth TJ, Sossi V, Schulzer M, Calne DB, et al. (2001) Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 293: 1164-1166.
6. Kemeny ME, Rosenwasser LJ, Panettieri RA, Rose RM, Berg-Smith SM, et al. (2007) Placebo response in asthma: a robust and objective phenomenon. J. Allergy Clin Immunol 119: 1375-1381.
7. Wechsler ME, Kelley JM, Boyd IOE, Dutile S, Marigowda G, et al. (2011) Active albuterol or placebo, sham acupuncture, or no intervention in asthma. N Engl J Med 365: 119-126.
8. Enck P, Benedetti F, Schedlowski M, (2008) New insights into the placebo and nocebo responses. Neuron 59: 195-206.
9. Tracey I, (2010) Getting the pain you expect: mechanisms of placebo, nocebo and reappraisal effects in humans. Nat Med 16: 1277-1283.
10. Benedetti F, Amanzio M, (2011) The placebo response: how words and rituals change the patient's brain. Patient Educ Couns 84: 413-419.
11. Benedetti F, Pollo A, Lopiano L, Lanotte M, Vighetti S, et al. (2003) Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. J Neurosci 23: 4315-4323.
12. Lidstone SC, Schulzer M, Dinelle K, Mak E, Sossi V, et al. (2010) Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychiat 67: 857-865.
13. Bingel U, Wanigasekera V, Wiech K, Ni Mhuircheartaigh R, Lee MC, et al. (2011) The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil. Sci Transl Med 3: 70ra14.
14. Colloca L, Tinazzi M, Recchia S, Le Pera D, Fiaschi A, et al. (2008) Learning potentiates neurophysiological and behavioral placebo analgesic responses. Pain 139: 306-314.
15. Ader R, (2003) Conditioned immunomodulation: research needs and directions. Brain Behav Immun 17: 51-57.
16. Longo DL, Duffey PL, Kopp WC, Heyes MP, Alvord WG, et al. (1999) Conditioned immune response to interferon-gamma in humans. Clin Immunol 90: 173-181.
17. Schedlowski M, Pacheco-López G, (2010) The learned immune response: Pavlov and beyond. Brain Behav Immun 24: 176-185.
18. Goebel MU, Trebst AE, Steiner J, Xie YF, Exton MS, et al. (2002) Behavioral conditioning of immunosuppression is possible in humans. FASEB J 16: 1869-1873.
19. Wirth T, Ober K, Prager G, Vogelsang M, Benson S, et al. (2011) Repeated recall of learned immunosuppression: evidence from rats and men. Brain Behav Immun 25: 1444-1451.
20. Niemi M-B, Härting M, Kou W, Del Rey A, Besedovsky HO, et al. (2007) Taste-immunosuppression engram: reinforcement and extinction. J Neuroimmunol 188: 74-79.
21. Grigoleit J-S, Oberbeck JR, Lichte P, Kobbe P, Wolf OT, et al. (2010) Lipopolysaccharide-induced experimental immune activation does not impair memory functions in humans. Neurobiol Learn Mem 94: 561-567.
22. Spielberger CD, Gorusch RL, Lishene RE (1970) Manual for the State-Trait Anxiety Inventory. Consulting Psychology Press: Palo Alto, CA.
23. Hautzinger M, Bailer M, Worall H, Keller F (1995) Beck-Depression-Inventar (BDI). Huber: Bern, Switzerland.
24. Ober K, Benson S, Vogelsang M, Bylica A, Günther D, et al. (2012) Plasma Noradrenaline and State Anxiety Levels Predict Placebo Response in Learned Immunosuppression. Clin Pharmacol Ther 91: 220-226.
25. Strafella AP, Ko JH, Monchi O, (2006) Therapeutic application of transcranial magnetic stimulation in Parkinson's disease: the contribution of expectation. Neuroimage 31: 1666-1672.
26. de la Fuente-Fernández R, Phillips AG, Zamburlini M, Sossi V, Calne DB, et al. (2002) Dopamine release in human ventral striatum and expectation of reward. Behav Brain Res 136: 359-363.
27. de la Fuente-Fernández R, (2009) The placebo-reward hypothesis: dopamine and the placebo effect. Parkinsonism Relat D 15: 72-74.
28. Doering BK, Rief W, (2012) Utilizing placebo mechanisms for dose reduction in pharmacotherapy. Trends Pharmacol Sci 33: 165-172.
29. Goebel MU, Meykadeh N, Kou W, Schedlowski M, Hengge UR, (2008) Behavioral conditioning of antihistamine effects in patients with allergic rhinitis. Psychother Psychosom 77: 227-234.
30. Ader R, Cohen N, (1982) Behaviorally conditioned immunosuppression and murine systemic lupus erythematosus. Science 215: 1534-1536.
31. Klosterhalfen S, Klosterhalfen W, (1990) Conditioned cyclosporine effects but not conditioned taste aversion in immunized rats. Behav Neurosci 104: 716-724.
32. Bovbjerg DH, (2003) Conditioning, cancer, and immune regulation. Brain Behav Immun 17: 58-61.
33. Gorczynski RM, Kennedy M, Ciampi A, (1985) Cimetidine reverses tumor growth enhancement of plasmacytoma tumors in mice demonstrating conditioned immunosuppression. J Immunol 134: 4261-4266.
34. Exton MS, Schult M, Donath S, Strubel T, Nagel E, et al. (1998) Behavioral conditioning prolongs heart allograft survival in rats. Transplant Proc 30: 2033.
35. Exton MS, Schult M, Donath S, Strubel T, Bode U, et al. (1999) Conditioned immunosuppression makes subtherapeutic cyclosporin effective via splenic innervation. Am J Physiol 276: 1710-1717.
36. Vits S, Cesko E, Enck P, Hillen U, Schadendorf D, et al. (2011) Behavioural conditioning as the mediator of placebo responses in the immune system. Philos T Roy Soc B 366: 1799-1807.
37. Bouton ME, (2002) Context, ambiguity, and unlearning: sources of relapse after behavioral extinction. Biol Psychiat 52: 976-986.
38. Hadamitzky M, Engler H, Schedlowski M (2012) Learned immunosuppression: extinction, renewal, and the challenge of reconsolidation. J Neuroimmune Pharm (In press).
39. Pacheco-López G, Niemi M-B, Kou W, Härting M, Fandrey J, et al. (2005) Neural substrates for behaviorally conditioned immunosuppression in the rat. J Neurosci 25: 2330-2337.
40. Exton MS, Gierse C, Meier B, Mosen M, Xie Y, et al. (2002) Behaviorally conditioned immunosuppression in the rat is regulated via noradrenaline and beta-adrenoceptors. J Neuroimmunol 131: 21-30.